Movement Alert｜Hims & Hers Health Inc. Rises 5.26% in Regular Trading, CEO Publicly Rebuts FTC Lawsuit Boosting Market Confidence

Market Focus08-19 22:09

On August 19, Hims & Hers Health Inc. rose 5.26% in regular trading, trading at $29.04/share, with turnover of $104 million. The rally was driven by CEO Andrew Dudum's public rebuttal of FTC allegations during a CNBC interview.

Dudum addressed the FTC's claims that the company shared user health data with Meta and Snap, engaged in billing violations, and created subscription cancellation barriers. He characterized the allegations as stemming from misunderstandings of the company's business model, emphasizing that Hims & Hers is a \"positive disruptor\" focused on expanding healthcare accessibility. The FTC lawsuit, filed on July 30, had previously triggered a 12% single-day decline.

Management's assertive stance alleviated investor concerns surrounding the legal proceedings. The recovery was further supported by recent analyst upgrades, including Needham raising its target price to $42 and Morgan Stanley adjusting its target to $28 from $21. The company recently reported Q2 revenue of $753 million, up 38% year-over-year, and raised its full-year revenue guidance to $3.1-3.3 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1102880527?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-19 22:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102880527","market":"us","top_or_hot":-1,"title":"Movement Alert｜Hims & Hers Health Inc. Rises 5.26% in Regular Trading, CEO Publicly Rebuts FTC Lawsuit Boosting Market Confidence","media":"Market Focus","content":"<p><p>On August 19, Hims & Hers Health Inc. rose 5.26% in regular trading, trading at $29.04/share, with turnover of $104 million. The rally was driven by CEO Andrew Dudum's public rebuttal of FTC allegations during a CNBC interview.</p><p>Dudum addressed the FTC's claims that the company shared user health data with Meta and Snap, engaged in billing violations, and created subscription cancellation barriers. He characterized the allegations as stemming from misunderstandings of the company's business model, emphasizing that Hims & Hers is a \\\"positive disruptor\\\" focused on expanding healthcare accessibility. The FTC lawsuit, filed on July 30, had previously triggered a 12% single-day decline.</p><p>Management's assertive stance alleviated investor concerns surrounding the legal proceedings. The recovery was further supported by recent analyst upgrades, including Needham raising its target price to $42 and Morgan Stanley adjusting its target to $28 from $21. The company recently reported Q2 revenue of $753 million, up 38% year-over-year, and raised its full-year revenue guidance to $3.1-3.3 billion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hims & Hers Health Inc. Rises 5.26% in Regular Trading, CEO Publicly Rebuts FTC Lawsuit Boosting Market Confidence</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hims & Hers Health Inc. Rises 5.26% in Regular Trading, CEO Publicly Rebuts FTC Lawsuit Boosting Market Confidence\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-19 22:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 19, Hims & Hers Health Inc. rose 5.26% in regular trading, trading at $29.04/share, with turnover of $104 million. The rally was driven by CEO Andrew Dudum's public rebuttal of FTC allegations during a CNBC interview.</p><p>Dudum addressed the FTC's claims that the company shared user health data with Meta and Snap, engaged in billing violations, and created subscription cancellation barriers. He characterized the allegations as stemming from misunderstandings of the company's business model, emphasizing that Hims & Hers is a \\\"positive disruptor\\\" focused on expanding healthcare accessibility. The FTC lawsuit, filed on July 30, had previously triggered a 12% single-day decline.</p><p>Management's assertive stance alleviated investor concerns surrounding the legal proceedings. The recovery was further supported by recent analyst upgrades, including Needham raising its target price to $42 and Morgan Stanley adjusting its target to $28 from $21. The company recently reported Q2 revenue of $753 million, up 38% year-over-year, and raised its full-year revenue guidance to $3.1-3.3 billion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1102880527","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102880527","pubTimestamp":1787148552,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 19, Hims & Hers Health Inc. rose 5.26% in regular trading, trading at $29.04/share, with turnover of $104 million. The rally was driven by CEO Andrew Dudum's public rebuttal of FTC...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"动态警报|Hims & Hers Health Inc. 常规交易上涨 5.26%，首席执行官公开反驳 FTC 诉讼提振市场信心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"On August 19, Hims & Hers Health Inc. rose 5.26% in regular trading, trading at $29.04/share, with turnover of $104 million. The rally was driven by CEO Andrew Dudum's public rebuttal of FTC allegations during a CNBC interview.Dudum addressed the FTC's claims that the company shared user health data with Meta and Snap, engaged in billing violations, and created subscription cancellation barriers. He characterized the allegations as stemming from misunderstandings of the company's business model, emphasizing that Hims & Hers is a \\\"positive disruptor\\\" focused on expanding healthcare accessibility. The FTC lawsuit, filed on July 30, had previously triggered a 12% single-day decline.Management's assertive stance alleviated investor concerns surrounding the legal proceedings. The recovery was further supported by recent analyst upgrades, including Needham raising its target price to $42 and Morgan Stanley adjusting its target to $28 from $21. The company recently reported Q2 revenue of $753 million, up 38% year-over-year, and raised its full-year revenue guidance to $3.1-3.3 billion.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1102880527","isCrawlerRequest":true}